A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 (3rd June)
Many have asked about my Parker Pen, this is the link to buy one (I receive a small commission if you use this link)
Amazon shop for my video production equipment (I receive a small commission if you use this link)
BACKGROUND
Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.
METHODS
Randomized, double-blind, placebo-controlled trial
United States and Canada
Testing hydroxychloroquine as postexposure prophylaxis
High risk, less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield
Moderate risk, while wearing a face mask but no eye shield
n = 821 asymptomatic participants (719 of 821) reported a high-risk exposure
Randomly assigned, placebo or hydroxychloroquine groups within 4 days of exposure
Primary outcome, incidence positive test of clinical diagnosis
RESULTS
Incidence of new illness
Hydroxychloroquine group (49 of 414), 11.8%
Placebo group (58 of 407), 14.3%
P=0.35
Side effects in hydroxychloroquine group = 40.1%
Side effects in control group = 16.8%
No serious adverse reactions were reported.
(Nausea, upset stomach, dizziness, headache)
Hydroxychloroquine group
Taking zinc 15% developed new disease
Not taking zinc 10.8% developed new disease
Placebo group
Taking zinc 15.4% developed new disease
Not taking zinc 14% developed new disease
Relative risk with zinc use was 1.23
Hydroxychloroquine group
Taking Vit C 14.3% developed new disease
Not taking Vit C 10.6% developed new disease
Placebo group
Taking Vit C 20.8% developed new disease
Not taking Vit C 11.2% developed new disease
Relative risk with vitamin C use was 1.60
The Lancet (and NEJM)
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, (May 22nd)
Serious scientific questions about the validity of data
‘Expression of Concern’
Issued a correction regarding location of some patients
Conclusions were not changed.
WHO resumed its trial of hydroxychloroquine
Crisis of trust
Medical journals
WHO
Governments
Scientific / medical advisors
